Navigation Links
Doubling Time on Tamoxifen Cuts Odds for Breast Cancer's Return: Study
Date:6/2/2013

SUNDAY, June 2 (HealthDay News) -- When it comes to using the drug tamoxifen to prevent breast cancer's return, longer may be better for some patients, a new study finds.

Women combating estrogen-sensitive breast tumors fared better when treated with 10 years of tamoxifen compared to those given the current standard of five years, researchers found.

However, longer tamoxifen regimens were associated with a greater risk for side effects from the cancer-suppressing drug, such as night sweats, hot flashes, blood clots, strokes and a heightened risk for cancer of the lining of the uterus (endometrial cancer).

Still, the investigation found that 10 years of treatment gave patients better protection against the recurrence of estrogen receptor (ER)-positive breast cancers and/or death than did treatments offered for half as long.

Assessing the findings in conjunction with the results of another recently completed study called the ATLAS trial, the team concluded that the benefits of prolonged therapy still outweigh any risks.

The study was scheduled for presentation Sunday in Chicago at the annual meeting of the American Society of Clinical Oncology (ASCO).

Five years of tamoxifen "is already an excellent treatment but we thought that longer treatment might be even better because women with ER-positive breast cancer can have recurrences long after treatment is completed," study lead author Richard Gray, professor of medical statistics at the University of Oxford in the United Kingdom, said in an ASCO news release.

"Until now, though, there have been doubts whether continuing tamoxifen beyond five years is worthwhile," he added. "This study and its international counterpart ATLAS confirm that there is definitely a survival benefit from longer tamoxifen treatment and many doctors will likely recommend continuing tamoxifen for an extra five years."

The research was funded by Cancer Research UK and the UK Medical Research Council. Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.

The study involved nearly 5,000 British breast cancer patients, all of whom had already completed a five-year regimen of tamoxifen by the time they entered the study at some point between 1991 and 2005.

In turn, half the women were randomly assigned to continue the medication for another five years, while half stopped the treatment altogether.

The result: no appreciable difference was found in death or breast cancer recurrence when assessing the impact of the sixth to ninth years of continued treatment.

However, when looking long-term -- at the 10th year and beyond -- the team found that the longer treatment option was having an impact. For example, breast cancer recurrence was lower among the 10-year group than the five-year group, at 16.7 percent versus 19.3 percent, respectively.

What's more, continuing treatment for double the usual period also reduced the overall risk of dying from breast cancer, the team noted.

"These results are therefore practice-changing for premenopausal women with hormone receptor-positive breast cancer and especially relevant for women who are at high risk of recurrence," Dr. Sylvia Adams, an ASCO spokesperson and breast cancer expert, said in the ASCO news release.

More information

There's more on estrogen and cancers at the U.S. National Cancer Institute.

-- Alan Mozes

SOURCE: American Society of Clinical Oncology, news release, June 2, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Doubling down on heart failure: Researchers discover new route to disease, and drugs to match
2. Doubling down against diabetes
3. Doubling Up on Cold, Flu Remedies May Harm Liver
4. Doubling Tamiflu Dose for Severe Flu Doesnt Help: Study
5. Possible therapy for tamoxifen resistant breast cancer identified
6. New finding gives clues for overcoming tamoxifen-resistant breast cancer
7. 10 Years of Tamoxifen Better Than 5: Study
8. Tamoxifen trial should prompt breast cancer patients to reconsider treatment options
9. Ability to metabolize tamoxifen affects breast cancer outcomes, Mayo Clinic-led study confirms
10. Genes Linked to Effectiveness of Tamoxifen for Breast Cancer
11. Researchers identify new pathway, enhancing tamoxifen to tame aggressive breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Doubling Time on Tamoxifen Cuts Odds for Breast Cancer's Return: Study
(Date:5/24/2016)... ... 2016 , ... Jericho Project has named LaToya Williams-Belfort to the position of ... fundraising and communications for the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and ... homelessness at its roots. , “LaToya Williams-Belfort is joining Jericho at an exciting ...
(Date:5/24/2016)... ... May 24, 2016 , ... Local engineering firm, ... Virginia Medical Center located in Woodbridge, VA. The project includes a brand ... single site. , The new 2 story building houses the Central Sterile department, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Regenerative Medicine is being transformed by ongoing ... therapy technology, protocols and patient results as have been achieved with Okyanos Cell ... accessible standard of care for patients worldwide. , As the Medical Advisory Chairman at ...
(Date:5/24/2016)... ... May 24, 2016 , ... Boyd Industries, a leading supplier of ... groundbreaking new product for pediatric dentistry , at AAPD 2016, the annual conference ... May 26-29. The Concealed Delivery Unit keeps dental hand pieces and other anxiety-provoking pieces ...
(Date:5/24/2016)... ... May 24, 2016 , ... Growing in popularity, more and more people ... are available and easily accessible. Whether someone chooses to cut gluten out of their ... diet, King Kullen Grocery stocks their shelves with many different gluten-free products all year ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president ... today. In his new role, Marziani will lead the company,s business development and sales ... improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... May 24, 2016 Open Access ... Clinical Neurophysiology  Elsevier , a world-leading ... services, today announced the launch of Clinical ... journal that focuses on clinical practice issues in clinical ... clinical series, normal values and didactic reviews. It is ...
(Date:5/23/2016)... 2016 Global Paclitaxel Market 2016 ... 12 companies and the Paclitaxel analysis in this study ... industry and its players. This is the ... details the current state of the industry while providing ... applications and industry chain structure. The Paclitaxel market analysis ...
Breaking Medicine Technology: